OSE 2101

Drug Profile

OSE 2101

Alternative Names: EP-2101; IDM 2101; OSE-2101; Tedopi

Latest Information Update: 11 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator IDM Pharma
  • Developer OSE Immunotherapeutics
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Breast cancer; Colorectal cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 07 Dec 2017 Independent Data Monitoring Committee recommends resuming patient enrolment in the phase III Atalante 1 trial for non-small cell lung cancer, albeit with a new recruitment strategy
  • 07 Sep 2017 OSE Immunotherapeutics in collaboration with GERCOR plans a phase II trial for Pancreatic Cancer (Combination therapy, Late stage, metastatic disease)
  • 06 Sep 2017 OSE Immunotherapeutics and GERCOR agree to co-develop OSE 2101 France for Pancreatic cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top